Skip to main content

Advertisement

Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

From: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Parameter KRAS-wildtype All patients KRAS-mutant
Specificity 0.74 0.71 0.78
Sensitivity 0.80 0.80 1.00
PPV 0.76 0.63 0.33
NPV 0.78 0.86 1.00
  1. NPV: negative predictive value; PPV positive predictive value